4Kerst JM , Bex A, Mallo H, et al. Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase Ⅱ study [J], Cancer Immunol Irnmunother, 2005,54(9):926-9:31. Epub 2005,May 19.
5Drnoszynska A, Podhorecka M, Manko J, et al. The influence of thalidomide therapy on cytokine secretion, immunophenotype, 13CL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma [J]. Neoplasma, 2005,52(2) : 175-181.
6Grzasko N, Dmoszynska A, Hus M, et al. Stimulation of erythropoiesis by thalidomide in multiple myelorna patients: its influence on FasL, TRAIL and their receptors on erythroblasts[J]. Haematologica, 2006,91 (3) : 386-389.
7Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product[J]. Drug Diseov Today, 2005, 10(2) :107-114.
8Settles B, Stevenson A, Wilson K. Down-regulation of cell adhesion molecules LFA-1 and 1CAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide [J]. Cell Mol Biol (Noisy-le-grand), 2001, 47(7):1 105-1 114.
9Zhou S, Kestell P, Paxton JW. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation [J] . Drug Metab Rev, 2002,34(4):751-790.
3S. Singhal,J. Mehta,Thalidomide in cancer,Biomed Pharmacother,2002,56(1): 4-12.
4Macpherson GR, Franks M, Tomoaia-Cotisel A et al. Current status of thalidomide and its role in the treatment of metastatic prostate cancer[J].Critical Reviews in Oncology/Hematology,2003,46:S49-/S57
5Bisacchi D, Benelli R, Vanzetto C et al.Anti-angiogenesis and angioprevention:mechanisms,problems and perspectives[J].Cancer Detection and Prevention,2003,27(3):229-38.
6Musto P. Thalidomide therapy for myelodysplastic syndromes:current status and future perspectives[J].Leukemia Research,2004,28(4):325-32.
7Kenyon BM, Fiona Browne, D'amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization[J].Exp Eye Res,1997,64(6):971-8.
8Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent[J].Biochemical Pharmacology,1998,55(11):1827-34.
9Myounga H, Hongb SD, Kima YY et al.Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma[J].Cancer Letters,2001,163(2):191-200.
10Amato RJ. Thalidomide therapy for renal cell carcinoma,Critical Reviews in Oncology/Hematology,2003,46:S59-/S65.
3Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy[J]. Blood,2000,96:2 943 - 2 950.
4Nicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications [J]. Blood,2002, 99:4 525 -4 530.
5Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myeloflbrosis with myeloid metaolasia [ J ]. Br J Haematol, 2002,117 (2) : 288,296.
6Strupp C, Germing U, Aivado M. Thalidomide for the treatment of patients with myelodysplastic syndromes [ J ]. Leukemia, 2002,16 : 1 - 6.
7Deborah A Thomas, Francis J Giles, Maher Albitar. Thalidomide Thera- py for Myelofibrosis with Myeloid Metaplasia[ J]. Cancer, 2006,106 : 1 974 - 1 984.
8Mesa RA, Elliott MA, Schroeder G, et al. Durable responses to thalido- mide- based dmg therapy for myelofibrosis withmyeloid metaplasia [ J ]. Mayo Clin Proc,2004,79 (7) :883 -889.
9Mesa RA,David P Steensma,Animesh Pardanani,et al. Aphase 2 tri- al of combination low- dose thalidomide and prednisone for the treat-ment of myelofibrosis with myeloid metaplasia[J]. Blood,2003, 101: 2 534-2541.
10Weinkove JR, Reilly JT, MeMullin MF, et al. Low-dose thalidomide in myclofibrosis[J]. Haematologiea,2008,93 (7) : 1 100 - 1 101.
